Women’s health brand Perelel released clinical findings this week for its Triple-Support Protein, a three-in-one supplement that combines low-FODMAP prebiotic fiber, plant-based protein, and creatine monohydrate. The four-week randomized, double-blind, placebo-controlled trial tracked 39 women aged 30–60 and found that daily use improved LDL cholesterol levels, increased feelings of fullness, and boosted spatial memory performance.
The company said the results support the formula’s role in memory performance, glucose regulation, and digestive health. It is a rare case of a supplement maker testing a complete finished product rather than just its individual ingredients, which have each been studied separately in the past.
Perelel says the study generated clinical evidence on the complete formula and its health benefits for this specific age group of women. They frame the research as part of a broader push to close gaps in women’s health, a field that has historically received less research funding than men’s health.
Related: Young adults fuel demand for joint health supplements
“We’ve always believed women deserve nutrition that is built around the science of their bodies — not a one-size-fits-all approach,” said Victoria Thain Gioia, co-founder of Perelel, in a statement. “This study takes that philosophy a step further by testing the complete formula in the women it was designed to serve.”
The ingredient breakdown works like this: plant-based protein supports muscle health and satiety, creatine monohydrate supports muscle strength and power with growing evidence for cognitive benefits, and the prebiotic fiber targets metabolic and digestive health. The combination is patent-pending.
Most clinical trials in the supplement space test isolated compounds in controlled lab settings, often on male subjects. What stands out here is the decision to test the finished consumer product on the exact demographic it’s marketed toward, which gives the findings a practical relevance that single-ingredient studies sometimes lack.
The latest research adds to Perelel’s prior clinical trials conducted in 2025 and 2026 for other products in its portfolio, including Conception Support Pack, Synbiotic Greens Powder, and Perimenopause Support Pack. The company has been steadily building what it calls a body of clinical evidence across its product line.
Related: Saucony Triumph 23 Now Just 90 Dollars
In November last year, Perelel secured a US$27 million investment to expand its clinically proven products. The round included Prelude Growth Partners alongside existing investors Unilever Ventures, Willow Growth Partners, and Selva Ventures.
Consumer demand appears to be moving in the same direction. Data from Innova Market Insights shows a 12% increase in women’s health and sports nutrition supplements between 2020 and 2024. That same data found that 36% of global female consumers reported taking vitamins or minerals related to their hormonal cycle. Brain and mood health claims lead among top product launches, with growing emphasis on supplements targeting blood pressure.
They say they use up-to-the-minute clinical research to bring science-backed formulations designed for real patient needs, with a high standard for quality and testing. Whether the broader supplement industry follows suit with more formula-level testing remains to be seen, but the pressure for evidence-backed products is clearly building.
